The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Urologic Diseases

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Urologic Diseases


Psychiatry related information on Urologic Diseases

  • Detrusor hyperreflexia is described in patients with neurological disorders, bladder outflow obstruction, persistent enuresis and in female incontinent patients with obvious neurological or urological disease [6].

High impact information on Urologic Diseases


Chemical compound and disease context of Urologic Diseases

  • MATERIALS AND METHODS: Two boys and 5 girls (mean age 10.9 years) with giggle incontinence, a positive family history of giggle incontinence (4 patients) and no evidence of urological disease were treated with methylphenidate for 1 to 5 years [12].
  • 3. Analysis of logarithmic transformed values (ng/mg creatinine) showed that patients with both neoplastic and non-neoplastic urological diseases had significantly higher ferritin levels than normal control subjects (P = 0.02) [13].
  • METHODS: From a large data basis, we found retrospectively only 29 children (10 below and 19 above two years of age at first examination) having had at least two Tc-99m mertiatide (Tc-99m MAG3) renographic explorations for various urological diseases, with a decrease of split function of at least 5% between the two examinations [14].
  • The urinary activities of alpha-naphthyl acetate esterases were measured for groups of bilharzial and nonbilharzial patients with benign urologic diseases and for others with bladder cancer [15].
  • Endoscopic management of urologic disease with the holmium laser [16].

Gene context of Urologic Diseases

  • Urinary EGF values were lower in patients with urological diseases of different etiologies than in normal controls (P < 0.005) [17].
  • Urinary carcinoembryonic antigen values have been determined in large numbers of specimens from patients with a variety of urologic diseases but most studies have recorded only single measurements at the time of diagnosis [18].
  • Specificity of AuraTek FDP was 96% for healthy subjects, 86% in patients with urological disease other than bladder cancer and 80% for patients under surveillance for bladder cancer but with a negative cystoscopic finding at the time of assay [19].
  • For each patient, the TMA slides contained a tissue core from the primary tumour, its invasion front and the normal renal parenchyma. bFGF serum levels were higher in RCC patients vs healthy volunteers (P<0.01) and vs patients with benign urologic diseases (P<0.01) [2].
  • More information is needed regarding CK20 expression in nonmalignant urological disease, to evaluate its use for routine screening purposes [20].

Analytical, diagnostic and therapeutic context of Urologic Diseases


  1. Isolated asymptomatic microhematuria: a cross-sectional analysis of test-positive and test-negative patients. Mohr, D.N., Offord, K.P., Melton, L.J. Journal of general internal medicine : official journal of the Society for Research and Education in Primary Care Internal Medicine. (1987) [Pubmed]
  2. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. Horstmann, M., Merseburger, A.S., von der Heyde, E., Serth, J., Wegener, G., Mengel, M., Feil, G., Hennenlotter, J., Nagele, U., Anastasiadis, A., Bokemeyer, C., Stenzl, A., Kuczyk, M. J. Cancer Res. Clin. Oncol. (2005) [Pubmed]
  3. Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism. Berger, R., Billups, K., Brock, G., Broderick, G.A., Dhabuwala, C.B., Goldstein, I., Hakim, L.S., Hellstrom, W., Honig, S., Levine, L.A., Lue, T., Munarriz, R., Montague, D.K., Mulcahy, J.J., Nehra, A., Rogers, Z.R., Rosen, R., Seftel, A.D., Shabsigh, R., Steers, W. Int. J. Impot. Res. (2001) [Pubmed]
  4. Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database. D'Ambrosio, G., Samani, F., Cancian, M., De Mola, C. Eur. J. Cancer Prev. (2004) [Pubmed]
  5. Adolescent hemodialysis: results of the 2000 ESRD Clinical Performance Measures Project. Frankenfield, D.L., Neu, A.M., Warady, B.A., Watkins, S.L., Friedman, A.L., Fivush, B.A. Pediatr. Nephrol. (2002) [Pubmed]
  6. Detrusor hyperreflexia: the effect of posture and pelvic floor activity. Mayo, M.E. J. Urol. (1978) [Pubmed]
  7. Risk factors for cancer of the renal parenchyma. McCredie, M., Ford, J.M., Stewart, J.H. Int. J. Cancer (1988) [Pubmed]
  8. Lower urinary tract symptoms after renal transplantation in children. Van der Weide, M.J., Cornelissen, E.A., Van Achterberg, T., de Gier, R.P., Feitz, W.F. J. Urol. (2006) [Pubmed]
  9. Quality of life after cystectomy and urinary diversion: an evidence based analysis. Gerharz, E.W., Månsson, A., Hunt, S., Skinner, E.C., Månsson, W. J. Urol. (2005) [Pubmed]
  10. Phosphoinositide signaling in urological disease. Theodorescu, D. J. Urol. (2003) [Pubmed]
  11. Potential risk factors associated with progressive renal damage in childhood urological diseases: the role of angiotensin-converting enzyme gene polymorphism. Brock, J.W., Adams, M., Hunley, T., Wada, A., Trusler, L., Kon, V. J. Urol. (1997) [Pubmed]
  12. Successful treatment of giggle incontinence with methylphenidate. Sher, P.K., Reinberg, Y. J. Urol. (1996) [Pubmed]
  13. Clinical significance of urinary ferritin excretion in patients with transitional cell carcinoma. Chow, N.H., Chang, C.J., Cheng, P.E., Tzai, T.S., Huang, C.M., Lin, J.S. Clin. Sci. (1995) [Pubmed]
  14. How to interpret a deterioration of split function? Piepsz, A., Ismaili, K., Hall, M., Collier, F., Tondeur, M., Ham, H. Eur. Urol. (2005) [Pubmed]
  15. Urinary alpha-naphthyl acetate esterases: a preliminary screening test for bladder cancer. El-Sewedy, S.M., Arafa, A.M., Mostafa, M.H., El-Zoghby, S.M. Cancer Detect. Prev. (1981) [Pubmed]
  16. Endoscopic management of urologic disease with the holmium laser. Delvecchio, F.C., Preminger, G.M. Current opinion in urology. (2000) [Pubmed]
  17. An assessment of immunoreactive epidermal growth factor in urine of patients with urological diseases. Chow, N.H., Tzai, T.S., Cheng, P.E., Chang, C.J., Lin, J.S., Tang, M.J. Urol. Res. (1994) [Pubmed]
  18. The clinical value of urinary carcinoembryonic antigen-like substances in urothelial cancer. Murphy, W.M., Vandevoorde, J.P., Rao, M.K., Soloway, M.S. J. Urol. (1977) [Pubmed]
  19. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. Schmetter, B.S., Habicht, K.K., Lamm, D.L., Morales, A., Bander, N.H., Grossman, H.B., Hanna, M.G., Silberman, S.R., Butman, B.T. J. Urol. (1997) [Pubmed]
  20. Urinary cytokeratin 20 as a marker for transitional cell carcinoma. Rotem, D., Cassel, A., Lindenfeld, N., Mecz, Y., Sova, Y., Resnick, M., Stein, A. Eur. Urol. (2000) [Pubmed]
  21. Diagnostic tests and tools in the evaluation of urologic disease: Part II. Hanson, K.A. Urologic nursing : official journal of the American Urological Association Allied. (2003) [Pubmed]
WikiGenes - Universities